← Moderna, Inc.
| Annual Trend | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue: | ||||||||||
| Cost of sales | $82.6m | $0 | $0 | $7.9m | $2.6b | $5.4b | $4.7b | $1.5b | $868.0m | |
| Research and development | $410.5m | $454.1m | $496.3m | $1.4b | $2.0b | $3.3b | $4.8b | $4.5b | $3.1b | |
| Selling, general and administrative | $64.7m | $94.3m | $109.6m | $188.3m | $567.0m | $1.1b | $1.5b | $1.2b | $1.0b | |
| Total operating expenses | $475.2m | $548.3m | $605.9m | $1.6b | $5.2b | $9.8b | $11.1b | $7.2b | $5.0b | |
| Loss from operations | ($269.4m) | ($413.3m) | ($545.7m) | ($763.1m) | $13.3b | $9.4b | ($4.2b) | ($3.9b) | ($3.1b) | |
| Interest income | $15.2m | $27.0m | $38.5m | $24.7m | $18.0m | $200.0m | $421.0m | $425.0m | $314.0m | |
| Loss before income taxes | — | — | ($515.0m) | ($744.0m) | $13.3b | $9.6b | ($3.9b) | ($3.6b) | ($2.8b) | |
| Provision for (benefit from) tax provision | ($80k) | $326k | ($695k) | $2.6m | $1.1b | $1.2b | $772.0m | ($46.0m) | $54.0m | |
| Net loss | ($255.9m) | ($384.7m) | ($514.0m) | ($747.1m) | $12.2b | $8.4b | ($4.7b) | ($3.6b) | ($2.8b) | |
| Basic (in usd per share) | — | — | ($1.55) | ($1.96) | $30.28 | $21.22 | ($12.34) | ($9.27) | ($7.25) | |
| Diluted (in usd per share) | — | — | ($1.55) | ($1.96) | $28.31 | $20.10 | ($12.34) | ($9.27) | ($7.25) | |
| Other expense, net | ($1.9m) | $1.8m | ($7.5m) | ($6.1m) | ($29.0m) | ($45.0m) | ($124.0m) | ($87.0m) | ($8.0m) |
Values abbreviated: b = billions, m = millions, k = thousands. Per share data in USD.